Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Priya S. Hibshman(University of North Carolina at Chapel Hill), David Wildes(Revolution Medicines (United States)), Clint A. Stalnecker(University of North Carolina at Chapel Hill), Melissa M. Ronan(Broad Institute), Tanner C. Dalton(Columbia University Irving Medical Center), Marie Ménard(University of California, San Francisco), Kristina Drizyte‐Miller(University of North Carolina at Chapel Hill), Connor J. Hennessey(Broad Institute), William P. Vostrejs(University of Pennsylvania), Yu Chi Yang(Revolution Medicines (United States)), Gulam A. Manji(NewYork–Presbyterian Hospital), Urszula N. Wasko(Revolution Medicines (United States)), Stephen A. Sastra(Columbia University Irving Medical Center), Stephen M. Lagana, Jacqueline A.M. Smith(Revolution Medicines (United States)), Natalie K. Barker(University of North Carolina at Chapel Hill), Miroslav Sekulic(NewYork–Presbyterian Hospital), Julien Dilly(Massachusetts Institute of Technology), Sha Tian(Macau University of Science and Technology), Yingyun Wang(Revolution Medicines (United States)), Kenneth Y. Tsai(Moffitt Cancer Center), Robert H. Vonderheide(University of Pennsylvania), Andrea Califano(Columbia University Irving Medical Center), Nicholas D. Socci, Jennifer A. Roth(Broad Institute), Laura E. Herring(University of North Carolina at Chapel Hill), Ben Z. Stanger(Cancer Research Institute), Mallika Singh(Revolution Medicines (United States)), Samantha B. Kemp(University of Michigan), Margo Orlen(UPMC Hillman Cancer Center), Michael A. Badgley(Columbia University Irving Medical Center), Basil Bakir(University of Pennsylvania), Matthew G. Rees(Broad Institute), John A. Chabot(Columbia University Irving Medical Center), Lingyan Jiang(Hainan University), Álvaro Curiel‐García(Columbia University Irving Medical Center), Amanda R. Decker-Farrell(Columbia University Irving Medical Center), Andrew J. Aguirre(Broad Institute), Rina Sor(University of Pennsylvania), Haley Courtney(Revolution Medicines (United States)), Marie C. Hasselluhn(Columbia University Irving Medical Center), Carmine F. Palermo(Columbia University Irving Medical Center), Cynthia Clendenin(University of Pennsylvania), Yevgeniy Gindin(Revolution Medicines (United States)), Ciara Helland(Revolution Medicines (United States)), Karl Muonio(Revolution Medicines (United States)), Timour Baslan(University of Pennsylvania), Jingjing Jiang(Revolution Medicines (United States)), A. Cole Edwards(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
|Immunity|1998|1.1k